RetractedArticleCNS oncology2016

ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.

Na Tosha N Gatson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.